Dafinchi
Factors Driving BIVIGAM Revenue Decline in Q1 2026: Market Dynamics Explored
An in-depth look into the key factors affecting BIVIGAM's revenue during Q1 2026, focusing on market competition, dislocation, and strategic implications.
Read post
Detailed company information
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 05, 2026
Earnings Transcript for 2026 - Q1Released: May 07, 2026
Earnings Transcript for 2025 - Q4Released: Feb 25, 2026
Earnings Transcript for 2025 - Q3Released: Nov 06, 2025
Earnings Transcript for 2025 - Q2Released: Aug 06, 2025
Earnings Transcript for 2025 - Q1Released: May 07, 2025
Earnings Transcript for 2024 - Q4Released: Mar 03, 2025
Earnings Transcript for 2024 - Q3Released: Nov 07, 2024
Earnings Transcript for 2024 - Q2Released: Aug 08, 2024
Earnings Transcript for 2024 - Q1Released: May 09, 2024
Earnings Transcript for 2023 - Q4Released: Feb 28, 2024
Earnings Transcript for 2023 - Q3Released: Nov 08, 2023
Earnings Transcript for 2023 - Q2Released: Aug 09, 2023
Earnings Transcript for 2023 - Q1Released: May 10, 2023
Earnings Transcript for 2022 - Q4Released: Mar 23, 2023
Earnings Transcript for 2022 - Q3Released: Nov 09, 2022
Earnings Transcript for 2022 - Q2Released: Aug 10, 2022
Earnings Transcript for 2022 - Q1Released: May 11, 2022
Earnings Transcript for 2021 - Q4Released: Mar 25, 2022
Earnings Transcript for 2021 - Q3Released: Nov 10, 2021
Earnings Transcript for 2021 - Q2Released: Aug 11, 2021
Earnings Transcript for 2021 - Q1Released: May 12, 2021
Earnings Transcript for 2020 - Q4Released: Mar 25, 2021
Earnings Transcript for 2020 - Q3Released: Nov 06, 2020
STOK Stoke Therapeutics, Inc.
An in-depth look into the key factors affecting BIVIGAM's revenue during Q1 2026, focusing on market competition, dislocation, and strategic implications.
Read post